Can Fayuvi FDA approval lift RARE stock further?

Ultragenyx Pharmaceutical shares surged 12.6% after FDA approval of Fayuvi, its gene therapy for Sanfilippo syndrome Type A, though the RARE stock remains down sharply year-to-date following a failed trial.

This story was originally reported by Economic Times — Markets. As an automated real-time news aggregator, NewsToolBar provides multi-perspective indexing and AI summarization while directing full readership directly to primary publisher sources.